EXPONENT, INC. (EXPO): what the price assumes

In the published model solve dated 2026-Q2, anchored at $71.53, EXPONENT, INC. (EXPO) is priced for +23.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-26.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/EXPO

Headline

FieldValue
TickerEXPO
CompanyEXPONENT, INC.
Sector / IndustryIndustrials
Current price$71.53/sh
CompositionEngineering and Other Scientific 85% / Environmental and Health 15%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)13.6%
Operating margin today20.2%
Margin compression (value-band)-6.6pp
Implied growth23.1%
Multiple paid27x operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.1% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history+0.93σ
cohort percentile (of 225 peers)70

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.30x4expensive
Earnings3.57x5expensive
Relative2.29x2expensive
Growth1.07x3expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$60.131.19xyesFCF base $0.1B, growth 13% (input: historical growth), terminal g 4.0%, WACC 8.8%, 6yr projection
DCF Exit MultipleGrowth$82.600.87xyesExit EV/EBITDA: 24.3x / 26.3x / 28.3x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelativenoP/E 21.73x (blended: static sector reference 18x + trailing (TTM) 30x), scenarios: 17.9x / 21.7x / 25.6x (bear / base = reference held flat / bull), EV/EBITDA 16.28x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$25.412.82xyesBV/sh $6.07, ROE (TTM) 38.7%, ke 9.3%
Two-Stage Excess ReturnAsset$57.191.25xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$67.141.07xyesRev $0.6B, growth 13% (input: historical growth; tapered), Terminal P/S: 4.4x / 5.4x / 6.3x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$26.642.69xyesEPS $2.22, growth 11% (input: historical EPS growth), PEG=2.67 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$16.594.31xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.12B × (1−28%) / WACC 8.8% → EPV (no growth)
Residual IncomeAsset$40.091.78xyesBV $6.07 + 5yr PV of (ROE (TTM) 38.7% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$17.414.11xyes√(22.5 × EPS $2.22 × BVPS $6.07) — Graham's conservative floor
EV/EBITDA RelativeRelativenoEBITDA $0.14B × sector EV/EBITDA 12.0x
FCF YieldEarnings$20.053.57xyesFCF $108.6M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$14.115.07xyesSBC-adj FCF $0.08B (FCF $0.11B − SBC $0.03B) capitalized at Kₑ
Ben Graham FormulaEarnings$58.151.23xyesEPS $2.22 × (8.5 + 2×11.4%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$2.7426.11xyesBV $6.07 × (ROIC 4.0% / WACC 8.8%) (excluded from median)
P/Sales SectorRelativenoRevenue $0.63B × sector P/S 2.5x
PEG Fair ValueRelative$37.891.89xyesEPS $2.22 × (PEG 1.5 × growth 11.4% (input: historical EPS growth)) → PE 17.1x
Earnings YieldEarnings$24.002.98xyesEPS $2.22 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Engineering and Other Scientificoperatingenterprise$493.9mwithheldunresolved no unit value
Environmental and Healthoperatingenterprise$88.1mwithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net cash$66.6m
Net debt / NOPAT (after-tax)-0.72x (net cash)
Net debt / operating income (pre-tax)-0.52x (net cash)
Share count CAGR (buyback)-1.7%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

The March 2026 quarter is the one to read closely, because the headline understates it. Revenues before reimbursements rose 10.5%, to 151.8 million dollars from 137.4 million. Income before taxes rose 12.1%, and net income 11.0%, giving diluted earnings of 59 cents against 52 cents. Reported operating income nonetheless fell, to 41.4 million dollars from 44.4 million, and the reason sits two lines further down: Exponent runs a deferred compensation plan whose asset values flow through compensation expense and are offset in other income. A year earlier that plan produced a 9.4 million dollar miscellaneous loss; this year it produced almost none. The swing moves reported operating profit around without touching what the business earned.

That distinction matters because the underlying acceleration is real. Fiscal 2025 revenue grew 4.2%, to 582.0 million dollars, and the engineering and scientific segment, which is nearly 85% of the business, grew 5.2% to 493.9 million. A quarter growing at better than double that pace is a change of direction, not a continuation.

What Exponent sells is difficult to compete away. The company is retained when something has failed and somebody needs an answer that will survive cross-examination: a battery fire, a structural collapse, a product recall. The filing is precise about why clients with in-house capability still hire it, noting that "Clients that have the capability to perform such services themselves will retain Exponent or other independent consultants because of independence concerns." Independence is not a service feature that a client can replicate internally by definition. It is the one thing an internal team can never supply.

The margin evidence supports the moat rather than merely asserting it. Exponent converts close to a fifth of gross revenue into operating profit. In the cohort of professional services firms it sits beside, ACCENTURE (ACN) manages 14.5%, KORN FERRY (KFY) 12.8%, HURON (HURN) 10.4%, FTI CONSULTING (FCN) 10.2% and BOOZ ALLEN (BAH) 9.2%. In the environmental and health comparison set, TETRA TECH (TTEK) runs 12.1% and AECOM (ACM) 6.3%. Exponent earns roughly half again what the best of them earns, on a fraction of their scale, which is what pricing power in a service business looks like when it is genuine.

The balance sheet imposes no constraints on any of it. There is no funded borrowing at all; the liabilities are leases, payroll accruals and a deferred compensation plan matched by its own assets. The company raised its quarterly dividend to 31 cents from 30 cents in the March quarter and has been shrinking its diluted share count, from 51.65 million a year ago to 50.12 million. A firm that needs no capital, carries no debt and returns its earnings has very few ways to destroy value.

Bear Case

Look at what Exponent actually owns and the fragility becomes visible. Total assets were 687.4 million dollars at April 3, 2026, of which property and leasehold improvements were 71.9 million and goodwill 8.6 million. There is no funded borrowing, which is usually presented as strength, and in one sense it is. But the absence of debt is also the absence of anything to lever, because there is nothing to lever against. The productive asset is 973 technical staff, and they are not on the balance sheet. They go home every night and can be hired by a competitor, or by a client, or can retire.

The cash pattern shows how completely the economics belong to those people. Cash fell from 221.9 million dollars at the start of January to 118.6 million by early April, while accrued payroll and employee benefits dropped from 121.3 million to 82.6 million. That is the annual bonus leaving the building. It happens every year, it is the honest cost of the business, and it means the firm carries no retained capital cushion of the sort a manufacturer accumulates. Under a stress scenario, a consultancy cannot cut its way to safety without cutting the asset that generates the revenue, and a bench of specialists who have been let go does not reassemble when demand returns.

Then there is what is driving the growth. Fiscal 2025 revenue rose 4.2%, but billable hours fell 2%, to 1,468,000 from 1,495,000, and utilisation was flat at 73%. Technical staff grew 1%. Strip that apart and the entire increase came from charging more per hour. Rate increases are the highest-quality growth a professional firm can have right up to the point where they stop, and there is no rule that says clients keep absorbing them while the hours they buy decline. The environmental and health segment already shows the other outcome: revenue there fell 1.0% in fiscal 2025.

Client concentration compounds it. The filing warns that the company derives a significant portion of revenue from clients in a handful of industries and that "The loss of any large client could have a material adverse effect on our business, financial condition or results of operations." Litigation-driven consulting is also lumpy by nature: a single large matter concluding can remove a meaningful block of hours with no notice, and nothing replaces it on a schedule.

Set that against what the price asks. Today's quote capitalises the trailing operating profit at roughly twenty-five times, and the implied requirement is high-teens annual growth in operating profit sustained across a five-year stage. Only about two in five comparable fast-growers have held such a pace that long. The methods say the same thing from another direction: what the company owns, what it earns today with no growth credited, and what peer multiples pay for comparable consultancies all land far beneath the quote, and only the forward-growth frame reaches it. That is a durability premium in its purest form. The business may well deserve one. What a buyer should understand is that at this price there is no other line of support underneath.

Valuation

Three numbers frame this one. Fiscal 2025 operating income was 119.8 million dollars, essentially flat on the 119.6 million of fiscal 2024, and the trailing figure through the March 2026 quarter is close to 116.7 million. An enterprise value near 2.9 billion dollars against that stream works out to roughly twenty-five times operating profit. For a consultancy that grew revenue 4.2% last year on fewer billable hours, the multiple carries a great deal of expectation.

The methods make the shape of that expectation explicit, and they are close to unanimous. Only the forward-growth approaches reach today's quote. The price sits at nearly three times where the no-growth earnings-power methods land, and well above where peer multiples and book-value-plus-profitability come out. When only one frame reaches the price and the rest are not close, the premium is not a modelling artefact; it is the market paying for continuation of an unusual position that static arithmetic cannot represent.

The unusual position is real enough to measure. Exponent turns close to a fifth of gross revenue into operating profit. In the consulting cohort, ACCENTURE (ACN) converts 14.5%, KORN FERRY (KFY) 12.8%, HURON (HURN) 10.4% and BOOZ ALLEN (BAH) 9.2%; in the environmental comparison set TETRA TECH (TTEK) converts 12.1% and AECOM (ACM) 6.3%. The gap is not small and it has persisted. A reader deciding whether the premium is deserved is really deciding whether independence in failure analysis is a durable franchise or a good position in a favourable era.

The composition of growth is where the doubt enters the arithmetic. Revenue rose 4.2% in fiscal 2025 while hours billed fell 2% and utilisation stayed at 73%; the engineering and scientific segment grew 5.2% while environmental and health fell 1.0%. Growth built entirely on rate has a different persistence profile from growth built on volume, and the implied requirement embedded in the price runs several times the pace the last full year delivered.

Solvency is the simplest part of the report. There is no funded borrowing. Liquid assets stood at 118.6 million dollars in early April, which is the low point of the annual cycle rather than a trend, since the yearly bonus is paid in the first quarter; counting lease obligations the net position is nearer 37.5 million on that same date. The company is not burning money, it pays a rising dividend, and its share count is falling. None of that supports the multiple; it simply means the multiple is the only thing a buyer has to be right about.

Catalysts

Second-quarter fiscal 2026 results and the accompanying call are set for July 30, 2026, a date the company announced on July 9, 2026. The March quarter that precedes it showed revenues before reimbursements up 10.5% and diluted earnings of 59 cents against 52 cents. The figure worth isolating in the July release is billable hours, since fiscal 2025 growth came from rate rather than volume, and a second consecutive quarter of double-digit revenue growth means something very different if the hours behind it have started rising.

The leadership change is the structural item. On April 6, 2026 the board appointed John Pye as president and Eric Anderson as chief financial officer, both effective May 1, 2026, with long-serving finance chief Richard Schlenker moving to executive vice president and standing for election to the board. Both appointees are internal, and Pye joined the firm in 1999, so this is a succession rather than a redirection. Even so, July 30 is the first full quarter reported under the new arrangement, and a new finance chief's first release is where reporting conventions tend to get revisited.

Two smaller items sit on the calendar behind those. The company hosted an investor day at its Phoenix test and engineering centre on June 17, 2026, which is where a firm of this kind shows the physical capacity behind the consulting revenue. And the quarterly dividend moved up to 31 cents a share in the March quarter from 30 cents, a small raise but a continued one, funded entirely from operating earnings rather than from borrowing.

Peer Cohorts (Per Segment, With Filing Citations)

Engineering and Other Scientific (reported)

Environmental and Health (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Exponent fiscal 2025 annual report · Exponent first-quarter 2026 report · Exponent Form 8-K, April 6, 2026 · Exponent fiscal 2025 annual report and first-quarter 2026 report · Exponent scheduling release, July 9, 2026 · Exponent investor day announcement, June 2026

View the full interactive EXPO report on boothcheck